Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice

Journal of Neuroscience

Volumn 19, Issue 7, 1999, Pages 2424-2431

  Fumagalli, Fabio ^a,b   Gainetdinov, Raul R ^a   Wang, Yan Min ^a   Valenzano, Kenneth J ^a,c   Miller, Gary W ^a,d   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c PHARMACOPEIA INC   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Dopamine; Free radicals; GFAP; Methamphetamine; Microdialysis; Vesicular monoamine transporter

Indexed keywords

METHAMPHETAMINE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR DISTRIBUTION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG ABUSE; KNOCKOUT MOUSE; MONOAMINE RELEASE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0033118563     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.19-07-02424.1999     Document Type: Article

References (64)

1. Albers DS, Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-1114.
2. Axt KJ, Commins DL, Vosmer G, Seiden LS (1990) α-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res 515:269-276.
3. Bannon MJ, Bunney EB, Roth RH (1981) Mesocortical dopamine neurons: rapid neurotransmitter turnover compared to other brain catecholamine system. Brain Res 218:376-382.
4. Bowyer JF, Tank AW, Newport GD, Slikker Jr W, Ali SF, Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in striatum. J Pharmacol Exp Ther 260:817-824.
5. Bowyer JF, Davied DL, Schmued L, Broening HW, Newport GD, Slikker Jr W, Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268: 1571-1580.
6. Brodie BB, Pletscher A, Shore PA (1955) Evidence that serotonin has a role in brain function. Science 122:968-972.
7. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Epstein CJ (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/ zinc superoxide dismutase transgenic mice. J Neurochem 62:380-383.
8. Callaway CW, Kuczensky R, Segal DS (1989) Reserpine enhances amphetamine stereolypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res 505:83-90.
9. Carlsson A (1987) Monoamines of the central nervous system: a historical perspective. In: Psychopharmacology: the third generation of progress (Meltzer HY, ed), pp 37-48. New York: Raven.
10. Chiueh CC, Murphy DL, Miyake H, Lang K, Tulsi PK, Huang SJ (1993) Hydroxyl free radical (-OH) formation reflected by salicylate hydroxylation and neuromelanin. In vivo markers for oxidant injury of nigral neurons. Ann NY Acad Sci 679:370-375.
11. Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M (1993) Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibition in vivo. J Pharmacol Exp Ther 265:103-111.
12. Coudray C, Talla M, Martin S, Fatome M, Favier A (1995) High-performance liquid-chromatography electrochemical determination of salycilate hydroxylation products as an in vivo marker of oxidative stress. Anal Biochem 227:101-111.
13. Cubells JF, Rayport S, Rajindron G, Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular stress. J Neurosci 14:2260-2771.
14. De Vito MJ, Wagner GC (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28:1145-1150.
15. Fairbrother IS, Arbuthnott GW, Kelly JS, Butcher SP (1990) In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals. I. Studies using veratrine and ouabain. J Neurochem 54: 1835-1843.
16. Fleckenstein AE, Wilkins D, Gibb JW, Hanson GR (1997) Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther 283:281-285.
17. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271-1283.
18. Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea pig striatum following reserpine treatment. J Neural Transm 76:155-161.
19. Franklin KBJ, Paxinos G (1996) The mouse brain in stereotaxic coordinates. San Diego: Academic.
20. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18:4861-4869.
21. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325.
22. Gainetdinov RR, Fumagalli F, Wang YM, Jones SR, Levey AI, Miller GW, Caron MG (1998a) Increased MPTP neurotoxicity in vesicular monoamine transporter knockout mice. J Neurochem 70:1973-1978.
23. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG (1998b) Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Rev 26:148-153.
24. Gibb JW, Kogan FJ (1979) Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase. Naunyn Schmiedebergs Arch Pharmacol 310:185-187.
25. Hotchkiss AJ, Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophane hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257-262.
26. Javoy F, Glowinsky G (1971) Dynamic characteristics of the "functional" compartment of dopamine in dopaminergic terminals of the rat striatum. J Neurochem 18:1305-1311.
27. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG (1998a) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
28. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998b) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986.
29. Lesch KP, Heils A, Riederer P (1996) The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes. J Mol Med 74:365-378.
30. Liu Y, Edwards RH (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 20:125-156.
31. Marek GJ, Vosmer G, Seiden LS (1990a) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res 513:274-279.
32. Marek GJ, Vosmer G, Seiden LS (1990b) The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res 516:1-7.
33. Mignot E, Laude D (1985) Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat csf after α-methyl-p-tyrosine. J Neurochem 45:1527-1533.
34. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI (1997) Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 41:530-539.
35. +. J Neural Transm 89:139-145.
36. O'Dell SJ, Weihmuller FB, Marshall JF (1991) Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res 564:256-260.
37. O'Dell SJ, Weihmuller FB, Marshall JF (1993) Methamphetamine-induced DA overflow and injury to striatal DA terminals: attenuation by DA D1 or D2 antagonists. J Neurochem 60:1792-1799.
38. Pifl C, Drobny H, Reither H, Hornykiewicz O, Singer EA (1995) Mechanism of the dopamine-releasing actions of amphetamines and cocaine: plasmalemmal dopamine transporter and vesicular monoamine transporter. Mol Pharmacol 47:368-373.
39. Pu C, Vorhees CV (1993) Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev Brain Res 72:325-328.
40. Reinhard Jr JF, Daniels AJ, Viveros OH (1988) Potentiation by reserpine and tetrabenazinc of brain catecholamine depletions by MPTP in the mouse: evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 90:349-353.
41. Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193:153-163.
42. Ricaurte GA, Fuller RW, Perry KW, Seiden LS, Schuster CR (1983) Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of D-methamphetamine and D-amphetamine. Neuropharmacology 22:1165-1169.
43. Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of hiogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263.
44. Schmidt CJ (1992) L-DOPA potentiates the neurotoxicity of some amphetamine analogues. Ann NY Acad Sci 648:343-344.
45. Schmidt CJ, Gibb JW (1985) Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonclic acid. Eur J Pharmacol 109:73-80.
46. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233:539-544.
47. Schuldiner S, Shirvan A, Linial M (1995) Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev 75:369-392.
48. Seiden LS, Ricaurte G (1987) Neurotoxicity of methamphetamine and related drugs. In: Psychopharmacology: the third generation of progress (Meltzer HY, ed), pp 359-365. New York: Raven.
49. Seiden LS, Sahol KE (1995) Neurotoxicity of methamphetamine-related drugs and cocaine. In: Handbook of neurotoxicology (Chang LW, Dyer RS, eds) pp 825-843. New York: Marcel Dekker.
50. Seiden LS, Vosmer G (1984) Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav 21:29-31.
51. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 32:639-677.
52. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102-4108.
53. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943.
54. Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43:555-560.
55. Varoqui H, Erickson JD (1997) Vesicular neurotransmitters transporters. Mol Neurobiol 15:165-192.
56. Wagner GC, Ricaurte G, Seiden LS, Schuster CR, Miller RJ, Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160.
57. Wagner GC, Lucot JB, Schuster CR, Seiden LS (1983) α-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res 270:285-288.
58. Wagner GC, Carelli RM, Jarvis MF (1985) Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Pathol Pharmacol 47:221-228.
59. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG (1997) Knockout of the vesicular monoamine transporter-2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285-1296.
60. Weihmuller FB, O'Dell SJ, Marshall JF (1993) L-DOPA pretreatment potentiates striatal dopamine overflow and produces dopamine terminal injury after a single dose of methamphetamine. Brain Res 623:303-307.
61. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996a) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
62. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, Niznik H, Hornykiewicz O, Pifl C, Kish S (1996b) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-726.
63. Wrona MZ, Yang Z, Zhang F, Dryhurst G (1997) Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. Natl Inst Drug Abuse Res Monogr 173:146-174.
64. Zetterstrom T, Sharp T, Collin AK, Ungerstedt U (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs: implications for the origin of extracellular DOPAC. Eur J Pharmacol 148:327-334.